Third Harmonic Bio, Inc. (NASDAQ:THRD) revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial ...
Enrolment in this trial is expected to continue through the first quarter of 2025. Satellos is on track to submit a Phase II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback